Zobrazeno 1 - 10
of 46
pro vyhledávání: '"David F. Claxton"'
Autor:
Shin Mineishi, Pan Zheng, Robert F. Paulson, W. Christopher Ehmann, Hiroko Shike, Bei Jia, K. Sandeep Prabhu, Todd D. Schell, Yi Zhang, Chenchen Zhao, Michael G. Bayerl, Hong Zheng, David F. Claxton, Leonard D. Shultz
Publikováno v:
J Leukoc Biol
The prognosis for acute myeloid leukemia (AML) relapse post allogeneic hematopoietic stem cell transplantation (alloSCT) is dismal. Novel effective treatment is urgently needed. Clinical benefit of alloSCT greatly relies on the graft-versus-leukemia
Autor:
R.L. Bayer, Jerald P. Radich, Maria Brown, M. Lynn Savoie, Bruno C. Medeiros, Harry P. Erba, John M. Pagel, Selina M. Luger, Stephen A. Strickland, Sanjay R. Mohan, Guillermo Garcia-Manero, Dennis L. Confer, David A. Rizzieri, Stephen R. Spellman, Richard Stone, Geoffrey L. Uy, David F. Claxton, Mark R. Litzow, Min Fang, Frederick R. Appelbaum, Megan Othus, Mikkael A. Sekeres, Jeffrey Chell, Bayard L. Powell, James Essell, Guido Marcucci, Anna Moseley, Richard A. Larson, Tara L. Lin
Publikováno v:
JCO Oncol Pract
PURPOSE: Patients with acute myeloid leukemia with high-risk cytogenetics in first complete remission (CR1) achieve better outcomes if they undergo allogeneic hematopoietic cell transplantation (HCT) compared with consolidation chemotherapy alone. Ho
Autor:
Jeff Sivik, Chenchen Zhao, Natthapol Songdej, Todd D. Schell, Witold B. Rybka, David F. Claxton, Seema Naik, Hong Zheng, Ming Wang, W. Christopher Ehmann, Bei Jia, Raymond J. Hohl, Hui Zeng, Shin Mineishi
Publikováno v:
British Journal of Haematology
Summary Decitabine is a DNA‐hypomethylating agent that has been widely applied for the treatment of acute myeloid leukaemia (AML) patients who are elderly or unfit for intensive therapy. Although effective, the complete response rate to decitabine
Autor:
Charyguly Annageldiyev, Nicole R. Keasey, Emily Sullivan, Paul T. Toran, Hong Gang Wang, Regina M. Ondrasik, Su Fern Tan, Andrea L. Cote, Tye G. Deering, Todd E. Fox, David J. Feith, Brian M. Barth, Timothy J Brown, Stephan T. Stern, Mark Kester, David F. Claxton, Thomas P. Loughran, Vasiliki Papakotsi, Arati Sharma, Ross L. Levine, David B. Needle, Junjia Zhu, Sriram S. Shanmugavelandy, Aaron D. Viny, Viola Devine, Weiyuan Wang, Jason Liao
Publikováno v:
Blood Advances. 3:2598-2603
Key Points Distinct sphingolipid metabolism of AML with MDS-related changes defines unique sensitivity to nanoliposomal C6-ceramide. Vinblastine alters sphingolipid metabolism to enhance the sensitivity of AML to nanoliposomal C6-ceramide.
Autor:
Suming Huang, Dhimant Desai, Cesar Aliaga, Pavan Kumar Dhanyamraju, Sadie Steffens, Melanie A. Ehudin, Morgann Klink, Yali Ding, Mohammad Atiqur Rahman, Chunhua Song, Preeti Bhadauria, Arati Sharma, Chandrika Gowda, David F. Claxton, Soumya Iyer
Publikováno v:
Cancers
Volume 13
Issue 5
Cancers, Vol 13, Iss 1127, p 1127 (2021)
Volume 13
Issue 5
Cancers, Vol 13, Iss 1127, p 1127 (2021)
Simple Summary Acute Myeloid Leukemia is an aggressive disease with poor outcomes. New targeted therapies that can boost the effects of currently used chemotherapy medications without added toxicity are needed. Targeting an overactive kinase, called
Autor:
Qian Lai, Hongyu Ni, Shi Chen, Ying Guo, Huacheng Luo, Yi Qiu, Feng Chun Yang, David F. Claxton, Ganqian Zhu, Yang Feng, Suming Huang, Ru Feng, Jianfeng Xu, Bing Xu, Olga A. Guryanova, Stephen D. Nimer, Arati Sharma, Zhigang Zhao, Ruben A. Mesa, Wei Li, Mingjiang Xu
Publikováno v:
Nature Communications
Nature Communications, Vol 12, Iss 1, Pp 1-17 (2021)
Nature Communications, Vol 12, Iss 1, Pp 1-17 (2021)
Nucleophosmin (NPM1) is the most commonly mutated gene in acute myeloid leukemia (AML) resulting in aberrant cytoplasmic translocation of the encoded nucleolar protein (NPM1c+). NPM1c+ maintains a unique leukemic gene expression program, characterize
Autor:
Todd D. Schell, Jeffrey Sivik, Chenchen Zhao, Kevin Rakszawski, Hong Zheng, Raymond J. Hohl, Michael G. Bayerl, Bei Jia, David F. Claxton, Shin Mineishi, Hiroko Shike, W. Christopher Ehmann, Witold B. Rybka, Ming Wang, Joseph J. Drabick
Publikováno v:
Cancer Research. 79:1635-1645
Acute myeloid leukemia (AML) is a devastating blood cancer with poor prognosis. Immunotherapy targeting inhibitory pathways to unleash the antileukemia T-cell response is a promising strategy for the treatment of leukemia, but we must first understan
Autor:
Amit Verma, Selina M. Luger, Zhuoxin Sun, Puneet S. Cheema, Jaroslaw P. Maciejewski, Martin S. Tallman, Mark R. Litzow, David F. Claxton, Jessica K. Altman, Rami S. Komrokji, John M. Bennett, Alan F. List, Kathy L. McGraw, Ryan J. Mattison, Charles A. Schiffer, Andrew S. Artz, Timothy R. Wassenaar
Publikováno v:
J Clin Oncol
PURPOSE Impaired response to erythropoietin underlies ineffective erythropoiesis and anemia in myelodysplastic syndromes (MDS). We investigated whether treatment with lenalidomide (LEN), which augments erythropoietin receptor signaling in vitro, can
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b527e937e93c76976bde4e0ca2a12342
https://europepmc.org/articles/PMC8274743/
https://europepmc.org/articles/PMC8274743/
Autor:
Pinyi Lu, Longgui Chen, Barbara A. Miller, Zhongming Zhao, Charyguly Annageldiyev, Melat T. Gebru, Christopher M. Dower, Jennifer M. Atkinson, Arati Sharma, Megan M. Young, Zhenyuan Tang, Hong Gang Wang, Lijun Zhang, David F. Claxton, Yuka Imamura Kawasawa, Zhenqiu Liu
Publikováno v:
Blood
FLT3 is a frequently mutated gene that is highly associated with a poor prognosis in acute myeloid leukemia (AML). Despite initially responding to FLT3 inhibitors, most patients eventually relapse with drug resistance. The mechanism by which resistan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c7a15350f4c228b28961190773dd4afe
https://europepmc.org/articles/PMC7453151/
https://europepmc.org/articles/PMC7453151/
Autor:
Witold B. Rybka, Kristina Gvozdjan, Shin Mineishi, Hiroko Shike, Jozef Malysz, Carolyn Fisher, Heather Casey, Zheng Hong, Mike G Bayerl, Lorie H. Kumer, Maria Baker, Carrie L. Mowery, Jennifer Tyler, Christopher Ehmann, David F. Claxton, Seema Naik
Publikováno v:
Laboratory medicine. 51(6)
Chimerism testing by short tandem repeats (STRs) is used to monitor engraftment after allogeneic hematopoietic stem cell transplantation (HSCT). Generally, STR alleles are stable and transferred from parent to child or from donor to recipient. Howeve